Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Rapid-acting antidepressants (RAADs) such as ketamine are currently under development. The aim of this study is to characterize the neural circuits affected by ketamine and NLX-101, a selective 5-HT receptor biased agonist which has shown promising effects, by using [F]FDG PET imaging in rats that had received chronic administration of corticosterone (CORT), a model of anxiety-depression. In a longitudinal study, regional changes in brain activity were investigated in 24 selected CORT rats. Each animal underwent PET scans in 3 conditions, i.e. with ketamine (10 mg/kg), NLX-101 (0.16 mg/kg) or saline on day 0 and five days later to assess sustained effects. The anxious-depressive phenotype produced by CORT was supported by behavioural and biological observations. Changes in [F]FDG uptake were determined using voxel-based and region of interest analyses. Metabolic connectivity analysis was also performed to investigate the acute and delayed effects of the treatments. Voxel-based and region-of-interest analyses showed marked hypometabolism in regions implicated in depression, particularly cingulate cortex (-7%) and lateral septum (-9%) as well as the striatum (-10%). Acute effects of NLX-101 and ketamine were observed in the lateral septum, resulting in an increase in brain glucose metabolism (p < 0,05). Interestingly, connectivity analyses also showed effects of NLX-101 in the frontal cortex, the thalamus and amygdala (p < 0.05), suggesting that the two molecules converge on common brain regions. This study is the first to show brain activation patterns of RAADs in a CORT rat model by functional PET imaging. NLX-101 appears to exert antidepressant effects by preferentially activating postsynaptic 5-HT heteroreceptors in primary regions common to ketamine. These results support investigation of cortical 5-HT receptors as a target for new generation biased agonist antidepressants.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12402087PMC
http://dx.doi.org/10.1038/s41398-025-03572-4DOI Listing

Publication Analysis

Top Keywords

[f]fdg pet
8
effects nlx-101
8
5-ht receptor
8
receptor biased
8
biased agonist
8
lateral septum
8
effects
5
pet metabolic
4
metabolic patterns
4
patterns rapid-acting
4

Similar Publications

PET/CT imaging of the late-gestation fetal brain in pregnant rats: A proof-of-concept study.

J Cereb Blood Flow Metab

September 2025

Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.

Preclinical PET studies offer the opportunity to elucidate molecular mechanisms underlying early neurodevelopment with minimal invasiveness. We demonstrated the feasibility of fetal brain PET in four pregnant rats ( = 42 fetuses). [F]FDG uptake in rat fetuses was readily visualized by PET imaging.

View Article and Find Full Text PDF

Functional PET (fPET) identifies stimulation-specific changes of physiological processes, individual molecular connectivity and group-level molecular covariance. Since there is currently no consistent analysis approach available for these techniques, we present a toolbox for unified fPET assessment. The toolbox supports analysis of data obtained with a variety of radiotracers, scanners, experimental protocols, cognitive tasks and species.

View Article and Find Full Text PDF

Purpose: The liver-brain axis regulates metabolic homeostasis, with glucose metabolism playing a key role. Liver dysfunction, such as fibrosis, may impact brain metabolism and consequently, brain function. Positron emission tomography (PET) imaging provides a non-invasive approach to study glucose metabolism in both organs.

View Article and Find Full Text PDF

Background: Immunotherapy is a mainstay in the treatment of patients with advanced melanoma. Yet, resistance mechanisms exist, and tumour-associated macrophages (TAMs), particularly the M2-like phenotype, are associated with poorer outcomes, with CD206 serving as their specific marker. We present the first human SPECT/CT study to visualize CD206 + TAMs in patients undergoing immunotherapy and compare the findings to clinical outcomes (NCT04663126).

View Article and Find Full Text PDF